NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020
January 28, 2021 at 06:11 pm IST
Share
NGL Fine-Chem Limited announced earnings results for the third quarter ended December 31, 2020. For the third quarter, the company announced total revenue was INR 762.296 million compared to INR 386.091 million a year ago. Net income was INR 177.097 million compared to INR 11.273 million a year ago. Basic earnings per share from continuing operations was INR 28.67 compared to INR 1.82 a year ago. For the nine months, total revenue was INR 1,918.358 million compared to INR 1,187.765 million a year ago. Net income was INR 428.837 million compared to INR 85.034 million a year ago. Basic earnings per share from continuing operations was INR 69.41 compared to INR 13.76 a year ago.
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
NGL FINE-CHEM LIMITED 
